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a  b  s  t  r  a  c  t
Epidemics  of  seasonal  inﬂuenza  viruses  cause  considerable  morbidity  and  mortality  each  year.  Various
types and  subtypes  of  inﬂuenza  circulate  in  humans  and  evolve  continuously  such  that  individuals  at risk
of serious  complications  need  to be  vaccinated  annually  to keep  protection  up to  date  with  circulating
viruses.  The  inﬂuenza  vaccine  in  most  parts  of the  world  is a trivalent  vaccine,  including  an  antigenically
representative  virus  of recently  circulating  inﬂuenza  A/H3N2,  A/H1N1,  and  inﬂuenza  B  viruses.  How-eywords:
uadrivalent
rivalent vaccine
nﬂuenza B
edging
ever,  since  the  1970s  inﬂuenza  B has  split  into  two antigenically  distinct  lineages,  only  one  of  which  is
represented  in the  annual  trivalent  vaccine  at any  time.  We  describe  a lineage  selection  strategy  that  opti-
mizes  protection  against  inﬂuenza  B using  the standard  trivalent  vaccine  as a  potentially  cost  effective
alternative  to quadrivalent  vaccines.
ublisaccine strain selection
ecision tree
© 2016  The  Authors.  P
. Introduction
Inﬂuenza, a highly contagious respiratory disease in humans,
s associated with considerable morbidity and mortality and is
stimated to affect 5–15% of the world’s population annually [1].
ne important characteristic of inﬂuenza viruses is antigenic drift.
s population immunity builds up against circulating inﬂuenza
iruses, these viruses evolve to escape the immune response ren-
ering individuals susceptible to re-infection. Vaccination against
nﬂuenza is recommended for people at risk of developing serious
omplications when infected in most countries, and for all persons
ged ≥6 months in the United States [2], and has to be renewed
nnually to maintain protection.
The inﬂuenza virus vaccine in most parts of the world is a
rivalent vaccine, including an antigenic representative of recently
irculating inﬂuenza A/H3N2, A/H1N1, and inﬂuenza B virus strains.
wice annually, once for each hemisphere, WHO  recommends the
train of each of these inﬂuenza (sub)types to be included in the
accine, based on global surveillance data and substantial analyses
nd discussions of these data [3–7].The primary challenge in vaccine strain selection is to choose a
epresentative virus that antigenically matches the strains that will
irculate in the following inﬂuenza season. Typically the viruses
∗ Corresponding author at: University of Cambridge, Department of Zoology,
owning Street, Cambridge, CB23EJ, United Kingdom. Tel.: +44 (0)1223 330933.
E-mail address: derek.smith@antigenic-cartography.org (D.J. Smith).
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264-410X/© 2016 The Authors. Published by Elsevier Ltd. This is an open access
y-nc-nd/4.0/).hed  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
collected in the months immediately preceding a vaccine selection
decision are considered to be the best indicators of which viruses
will circulate in future inﬂuenza seasons [8]. However, inﬂuenza
B viruses present an additional challenge in that two  antigeni-
cally distinct lineages, B/Victoria (B/Vic) and B/Yamagata (B/Yam),
coexist, evolve separately, and alternate in prevalence in a so far
unpredictable pattern [9,10] (Fig. 1). This circumstance poses a
problem, because one of the two inﬂuenza B lineages is excluded
from the trivalent vaccine. The vaccine thus affords limited protec-
tion against inﬂuenza B when the opposite lineage to the vaccine
lineage circulates [10–12].
In case of a lineage-mismatch between the vaccine strain and
the circulating strain, a certain level of protection is still expected
as a result of the residual effect of prior years’ vaccination with
the circulating strain, and by a degree of cross-reactivity resulting
from the current vaccination event [13,14]. For example, a ran-
domized, placebo-controlled vaccine efﬁcacy study by Frey et al.
[11] during the 2007–2008 Northern Hemisphere inﬂuenza season
reports protection levels of 50% against the circulating B/Yam lin-
eage after vaccination with a trivalent vaccine containing a B/Vic
lineage strain. In years of mismatched vaccine B lineage, vaccine
efﬁcacy against the circulating strain is therefore unlikely zero
as has been assumed in a recent evaluation of the quadrivalent
vaccine [7].Table 1 shows the vaccine strain and the dominant circulating
strain in the US from 2000 to 2015. In periods when inﬂuenza B lin-
eages switch frequently vaccine efﬁcacy due to lineage mismatch
is considerable. For example, as previously observed [2,3], the
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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Fig. 1. Epidemic time series for B/Vic (red) and B/Yam (blue) based on virologically conﬁrmed data from the WHO  Collaborating Centers for Reference and Research on
Inﬂuenza. The counts of each variant are the numbers of viruses tested antigenically by the collaborating centers. Numbers are assumed to be representative of the relative
proportion of viruses that circulated. Time series were logged and smoothed with a weighted moving average to capture trends.
Table 1
Comparison of vaccine B lineage and circulating B lineages in the seasons 2000/2001–2011/2012. The last two columns indicate whether there was any antigenic drift within
each  of the two lineages between the vaccine strain selection and the inﬂuenza season. The strains Florida/06 and Massachusetts/12 belong to the same antigenic cluster.
The  strain s Wisconsin/10 and Phuket/13 belong to the same antigenic cluster.
Season Vaccine strain Dominant
circulating strain
Secondary strain (if
co-circulation)
Interim drift in Yam Interim drift in Vic
2000/2001 Yam—Beijing/93 Yam—Sichuan/99 None Some, SI/99 distinct
from BE/93
–
2001/2002 Yam—Sichuan/99 Vic—Brisbane/02 Yam—Sichuan/99 None –
2002/2003 Vic—Hong Kong/01 Vic—Brisbane/02 None None Some, BR/02
distinct from
HK/01
2003/2004 Vic—Hong Kong/01 Yam—Shanghai/02 None Some, SH/02 distinct
from SI/99
None, very little Vic
and BR/02-like
2004/2005 Yam—Shanghai/02 Yam—Shanghai/02 Vic—Brisbane/02 None None
2005/2006 Yam—Shanghai/02 Vic—Malaysia/04 Yam—Shanghai/02 None Some, ML/04
distinct from BR/02
and HK/01
2006/2007 Vic—Malaysia/04 Vic—Malaysia/04 Yam—Shanghai/02
& Florida/06
Minor, mainly genetic
change, SH/02 and
FL/06 antigenically
similar
None
2007/2008 Vic—Malaysia/04 Yam—Florida/06 &
Bangladesh/07
None Some, FL/06 and BA/07
different enough to
warrant vaccine update
None
2008/2009 Yam—Florida/06 Vic—Brisbane/08 Yam—Florida/06 &
Bangladesh/07
None Some, BR/08
distinct from
ML/04
2009/2010 Vic—Brisbane/08 Vic—Brisbane/08 very little Yam None None
2010/2011 Vic—Brisbane/08 Vic—Brisbane/08 Yam—Wisconsin/10 None None
2011/2012 Vic—Brisbane/08 Vic—Brisbane/08 Yam—Florida/06 &
Wisconsin/10
To previous Florida/06
like (except China
Wisconsin/10 like)
None
2012/2013 Yam—Wisconsin/10 Vic—Brisbane/08 Yam—Florida/06 &
Wisconsin/10
None None
2013/2014 Yam—Massachusetts/12 Yam—Wisconsin/10 Vic—Brisbane/08 To Wisconsin/10
everywhere
None
2014/2015 Yam—Massachusetts/12 Yam—Phuket/13 Vic—Brisbane/08 None None
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accine lineage and dominant circulating lineage have only coin-
ided in 50% of the years from 2000 to 2010. When lineage changes
re infrequent, such as between 2010 and the present, there is less
isk of decrease in vaccine efﬁcacy due to lineage mismatch. The last
ineage switch was in the northern hemisphere season 2012/2013.
t the time of this vaccine composition decision there had been
teadily increasing circulation of the B Yamagata lineage in recent
onths and years, but B/Yamagata was not predominant. For the
rst time population immunity to both lineages was part of the
onsideration in the switch to a B/Yam strain, and an update was
ade to a B/Yamagata virus in an anticipated, continued increase
n B/Yamagata viruses, and a recognition of solid immunity to
/Victoria viruses after four years of B/Victoria vaccination and no
ntigenic change in the B/Victoria viruses.
In this paper we compare three strategies to select the vaccine B
ineage in a trivalent inﬂuenza virus vaccine based on the long-term
verall protection rate expected from each strategy. First, the tradi-
ional lineage selection method that was used from 2001 onwards.
econd, a yearly alternation strategy where representative B/Vic
nd B/Yam viruses are used in alternating years to take advan-
age of residual protection levels. Third, a hedging strategy, which
n addition to residual protection takes into account the relative
ffects of titer decay over time, antigenic drift, and newcomers to
he annual vaccination program. We  compare these strategies by
stimating protection levels to vaccination with both lineages for
ach year between 2000 and 2010. We  then present a methodology
or optimal vaccine lineage selection for a trivalent vaccine based
n representative serum samples.
. Methods
.1. Antisera and titrations
Pre- and post-vaccination antisera were obtained from 2010
nﬂuenza vaccine trials in the United States, Australia, New
ealand, Japan and China (Table 2). Individuals had been vacci-
ated with a trivalent vaccine containing a B/Brisbane/60/2008-
ike virus, an A/California/7/2009 (H1N1)-like virus, and an
/Perth/16/2009 (H3N2)-like virus. Hemagglutination inhibition
HI) titers were measured to Brisbane/60/08 (the B/Vic lineage
irus), and to B/Wisconsin/1/10 (the contemporary B/Yam lineage
irus).
We created an additional dataset based on this vaccination
ata with an increased difference in pre-vaccination titers between
/Vic and B/Yam to approximate the difference one might expect
n the population after repeated years of vaccination with B/Vic. In
his transformation the B/Vic titers were multiplied by 1.5, and the
/Yam titers divided by 1.5.
.2. Calculation of expected post-titer values for hypothetical
accination with opposite lineageTo estimate the post-vaccination titers to a hypothetical vac-
ination with B/Yam we assumed that cross-reactivity between
he representatives of the two lineages was symmetric. To deter-
ine the titer boost to the vaccine and non-vaccine lineages after
able 2
umber of individuals in panel per country and age group, and age range where available
No. of adults No. of 
Australia 24 (23–58 y) 24 
US  24 24 
Japan  24 (20–58 y) 24 
China 30 (19–59 y) 30 
UK  24 24ine 34 (2016) 1617–1622 1619
vaccination, we performed a linear regression that predicts post-
vaccination titers from pre-vaccination titers. The regression was
done on an individual basis, by estimating the linear relationship
between log2 of the pre-vaccination titer (pre-titer) and log2 of the
post-vaccination titer (post-titer) for each of the lineage-match and
the non-lineage-match vaccination, to estimate the corresponding
post-vaccination titer for each individual.
We explored the relationship between pre-vaccination titer and
post-vaccination titer in the lineage-match case (“Match”) and
in the opposite lineage vaccination case (“NonMatch”) by run-
ning a linear regression for each subpopulation to ﬁnd the cMatch
and cNonMatch constants and intercepts and ßMatch and ßNonMatch
coefﬁcients
Post-titerVic = cMatch + ˇMatch × pre-titerVic
Post-titerYam = cNonMatch + ˇNonMatch × pre-titerYam
We then used the Match and NonMatch constants and
coefﬁcients to predict a hypothetical B/Vic post vaccination titer
HypVicPost and a B/Yam post vaccination titer HypYamPost that
would have resulted from a hypothetical vaccination with B/Yam,
by inverting them as follows:
HypVicPost = cNonMatch + ˇNonMatch × pre-titerVic
HypYamPost = cMatch + ˇMatch × pre-titerYam
3. Results
3.1. Comparison between three lineage selection strategies
3.1.1. The incumbent lineage strategy
The current practice for vaccine composition selects the anti-
genically most up-to-date strain of the B lineage circulating during
the most recent inﬂuenza season of the given hemisphere. This
ensures good protection levels against inﬂuenza B strains when
the previously dominant lineage continues to dominate.
3.1.2. The yearly alternation strategy
In the last decade of B lineage co-circulation, repeat years (in
which the same B lineage dominates as in the previous season)
appear to be neither more nor less frequent than years in which the
lineage has alternated. Given that it is not currently possible to pre-
dict which lineage will dominate the next season [9,10] (Table 1),
the yearly alternation strategy is simply to alternate the B lineage
in the vaccine on a yearly basis, one year a B/Vic lineage, the next
a B/Yam lineage, and so on. This strategy exploits residual cross-
reactivity to provide some protection to the lineage not included in
that year’s vaccine, from the previous year’ vaccination.
The yearly alternation strategy is based on the premise that any
person who has been in the vaccination program for at least one
year prior to the current vaccination will always have new pro-
tection against one strain, and one-year old residual protection to
the other. Overall protection levels would be improved because in
the 50% of year in which there will be a lineage-match protection
would be at full protection level just as in the incumbent lineage
.
elderly No. of pediatric
(61–83 y)
21 (8 mo–2 y)
(62–100 y)
(60–88 y) 29 (3–5 y)
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trategy, but in the remaining 50% non-lineage-match years the
esidual immunity would be higher as will be shown.
.1.3. The hedging strategy
Three sources of information, taken at the time of vaccine lin-
age choice, can inform the hedging strategy: number of years since
accination with either lineage, whether there has been antigenic
rift in either lineage during that time, and, if available, direct
erological assessment of residual protection levels in the popu-
ation. The hedging strategy chooses the B lineage for the vaccine
hat yields the highest expected vaccine efﬁcacy. The strategy is
ased on a decision tree, a standard tool in operations research
15], to assist in the choice between alternative options, in this case
etween B lineages in a trivalent vaccine.
Fig. 2 shows an example decision tree based on the North-
rn Hemisphere inﬂuenza season 2005–2006. The previous year’s
accine included a strain from the B/Vic lineage, and the year
revious to that, season 2003–2004, the vaccine included a
/Yam strain.
In this ﬁgure we show an example parameterization of the deci-
ion tree: vaccine-induced protection is 80% following vaccination,
ecaying to 60% after one year, and to 40% after two years, that drift
n a strain halves residual protection, and that 10% of each year’s
accinated population consists of naïve ﬁrst-time vaccinees. We
how in the Supplementary materials section S1 “Proof of gener-
lity of the basic model” that the hedging strategy provides higher
rotection in the interval 2000/2001–2011/2012 for all possible
arameter values. In order to choose a vaccine lineage the expected
accine efﬁcacy E(VE) is calculated for the two choices, either a
/Vic or a B/Yam vaccine component. In the case of this particu-
ar parameterization, the residual protection for the B/Vic lineage
s higher (54%) than for the B/Yam lineage (16%). This difference
s because the B/Yam lineage had not been in the vaccine for two
ears, and the B/Yam lineage had undergone drift during this time.
he expected overall vaccine efﬁcacy for inﬂuenza B from the B/Vic
train selected by the incumbent lineage strategy is 48%, whereas
he hedging strategy would choose a representative of B/Yam and
ield an expected overall vaccine efﬁcacy of 66%. Therefore, the
edging strategy would recommend, based on this decision tree,
he use of a B/Yam virus in the vaccine.
ig. 2. Example decision tree. A representative of B/Yam or B/Vic strain has to be chosen
ominates (outermost branches of the tree), or the non-vaccine lineage dominates (innerine 34 (2016) 1617–1622
In the case of lineage-mismatch, residual protection levels to the
non-vaccine strain are relatively high compared to when a vacci-
nated individual has not been vaccinated or naturally infected with
the circulating lineage for multiple years.
There are two  sources of improvement in vaccine efﬁcacy when
the B lineage used in the vaccine changes frequently. The residual
protection for the non-circulating lineage is higher, and there is also
a larger group of vaccinated individuals that have been vaccinated
with both strains within the last two  years. This is in sharp contrast
to the situation in which the last vaccination with the circulating
strain is several years earlier, in which case not only might indi-
viduals’ immunity have decreased substantially, but new entrants
to the vaccine program will have had no direct vaccine-induced
protection to the alternate lineage.
3.2. Theoretical comparison of the three lineage selection
strategies
To compare the three lineage-selection strategies, we evalu-
ated the expected protection levels over a ten-year period, from
2000 to 2010. Fig. 3 shows the expected protection levels based
on the example parameterization above (parameter values and
results in Table S2). For these years the hedging strategy yields
overall higher levels of E(VE) than the incumbent lineage strategy
and the yearly alternation strategy. The hedging strategy improves
protection against inﬂuenza B not by reducing the number of
lineage-mismatches, but by limiting their negative impact.
The hedging strategy yields the largest gains in situations where
the difference in pre-vaccination titers between the two lineages is
high.
3.3. Comparison of the three lineage selection strategies based on
serology data from vaccine re-registration trials
The yearly alternation strategy and the hedging strategy are
based on the assumption that vaccinating with the inﬂuenza B lin-
eage to which the population has lower antibody titers results in
greater overall expected protection levels for both lineages than
vaccinating with the lineage already associated with higher anti-
body titers. Above we have relied on estimates for pre-vaccination
 for the vaccine. Both choices lead to two  possible outcomes: the vaccine lineage
most branches of the tree).
A. Mosterín Höpping et al. / Vacc
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tig. 3. Predicted protection levels for the seasons 2000/2001 to 2009/2010 for each
f  the three lineage selection strategy.
iters, but for greater accuracy and reliability a population sample
ould be titrated ahead of the vaccine composition decision.
Ideally, shortly before the vaccine composition meeting, a
erologically representative population sample would be taken,
easuring titers against the most evolutionarily advanced repre-
entatives of B/Vic and B/Yam, and vaccinating with the lineage that
as lower protection levels.
To approximate the outcome of such a study, on data that has
he sort of heterogeneity that might be expected, we next generated
 sample dataset derived from an existing serological study, used
t the 2010/2011 Northern Hemisphere WHO  vaccine composition
eeting. In this dataset, titer levels to inﬂuenza B B/Vic and B/Yam
ere measured for a total of 303 individuals in the United States,
hina, the United Kingdom, Australia, and Japan before and after
accination with Brisbane/60/2008, a B/Vic lineage strain. From this
ataset we construct three additional datasets, one in which we
ake the raw data and approximate what would have happened if
accination had been against a virus in the other lineage, and then
wo others in which we artiﬁcially create a greater (and perhaps
ore likely in a random population) difference between B/Vic and
/Yam pre-titres (see Section 2), and estimate the effect of a B/Vic
nd B/Yam vaccination given these modiﬁed pre-titers.
A titer of 1:40 is widely used as a correlate of protection, as
t is thought to correspond to 50% protection. Therefore, we mea-
ure the proportion of titers above 40 to estimate vaccine outcome
protection rate) [16]. The average pre-vaccination protection rate
o B/Vic in the unadjusted 2010/2011 Northern hemisphere data
et is 50%, the average pre-vaccination protection rate to B/Yam is
6% (Table 3A).
able 3
verage population protection rates (proportion of population with titers ≥40). Post B/Vi
iters  ≥40. Post B/Yam vaccination protection rates are estimated based on the observed 
A Pre vaccination (%) Post B/Vic vaccination (%) 
Vic 49 88 
Yam  26 49 
Average 37.5 68.5 
Results  based on altered 2011 sera with a magniﬁed difference in pre-vaccination titers
B Pre vaccination (%) Post B/Vic vaccination (%) 
Vic 49 74 
Yam  10 25 
Average 29.5 49.5 ine 34 (2016) 1617–1622 1621
We calculated an overall post-vaccination protection rate as an
average of the protection rates to the two  lineages in Table 3, assum-
ing a 50% chance of either lineage circulating in the 2010/2011
season. In the unadjusted 2010/2011 Northern hemisphere data set
the difference in pre-vaccination titers between the two lineages
is small, and the hedging strategy accordingly results in a small
improvement over the incumbent lineage strategy. Given equal lin-
eage circulation probabilities, the overall protection rate against
inﬂuenza B in the 2010/2011 sample with the incumbent strategy
was 69%, but would have been 75% with the hedging strategy, giv-
ing an additional 6% of protected individuals at no extra cost. The
improvement of a quadrivalent vaccine is an increase in protection
rate from 69% to 94% (Table 3B), i.e., an additional 25% of protected
individuals.
In the dataset with a magniﬁed difference in pre-vaccination
titers, the pre-vaccination protection rate against B/Yam is 10%, and
against B/Vic is 49% (Table 3B). In this case, the expected protection
rate from the incumbent lineage strategy (vaccination with B/Vic) is
49.5%, and the expected protection rate from the hedging strategy
(vaccination with B/Yam) is 81%. The expected protection rate from
the quadrivalent vaccine is 87%. These results emphasize (given the
same probabilities of either lineage circulating) that the beneﬁt of
the hedging strategy is more pronounced when the initial differ-
ence in pre-vaccination titers is larger. They also illustrate how, in
any scenario, the hedging strategy provides the highest expected
protection rate of the three strategies.
4. Discussion
This study was performed to evaluate three inﬂuenza B vac-
cine lineage selection strategies. We  demonstrated that the hedging
strategy provided higher overall titer levels and superior protection
levels for individuals that are repeatedly vaccinated than either the
current incumbent lineage selection strategy, or an annual lineage
switch strategy.
A vaccination with either B lineage better for boosting titers to
that particular lineage. But in the absence of knowledge of which
lineage will circulate, overall a bigger improvement results from
vaccinating with the lineage that has the most unprotected indi-
viduals prior to vaccination. A strong increase of low titers coupled
with a weak increase of already high titers is overall more pro-
tective than a modest increase of previously high titers coupled
with a weak increase of low titers. The improvement provided by
the hedging strategy is expected to be larger in years when the
difference between pre-vaccination titers is larger than when the
difference between these titers is lower, but in any case always
exceeds the protection provided by the incumbent or alternating
lineage strategies.
Our results demonstrate that while the B/Vic and B/Yam lineages
circulate in a currently unpredictable pattern, it is best not to let
protection levels to either lineage drop too low, and to vaccinate
c vaccination protection rates are the proportion of individuals in the sample with
vaccine response (see Section 2). Results based on 2011 sera.
Post B/Yam vaccination (%) Post both vaccinations (%)
49 88
100 100
74.5 94
 between the two  lineages
Post B/Yam vaccination (%) Post both vaccinations (%)
62 74
100 100
81 87
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ith the lineage with lowest pre-vaccination titers. The hedging
trategy achieves higher overall protection than the incumbent lin-
age strategy by careful management of residual protection. The
uperiority of the hedging strategy is not that it achieves a higher
roportion of lineage-match years, but that it selects the B lin-
age so protection is higher than the incumbent lineage strategy
n non-lineage-match years.
For those vaccination programs and individuals who can afford
t, a quadrivalent vaccine avoids the need for a B lineage selec-
ion strategy for the vaccine. However, the majority of the world’s
nﬂuenza vaccine recipients currently receive a trivalent vaccine.
nalyses to compare the relative beneﬁts and cost effectiveness of
uadrivalent vaccines are ongoing [17–19]. We  have shown that
ome of the beneﬁt of transferring to a quadrivalent vaccine can be
aptured without the cost of moving to a quadrivalent vaccine with
n improved trivalent vaccine lineage selection approach. Individ-
als who receive a trivalent vaccine should beneﬁt from the best
ossible B selection strategy, and true cost-effectiveness studies
or quadrivalent vaccines should compare their added value to the
erformance of a trivalent vaccine based on the best possible B
ineage-selection strategy.
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